Global Investor Forum Contact

Hans Schikan

Board member of the Dutch Top Sector Life Sciences & Health

Hans Schikan has more than 25 years´ experience in senior management and Board level positions within the global biopharmaceutical industry. He was most recently the CEO of Prosensa, a biopharmaceutical company focusing on novel treatments for rare diseases like Duchenne muscular dystrophy, myotonic dystrophy and Huntington’s disease, using its RNA modulation platform. Prosensa was listed on NASDAQ (RNA) in June 2013, and was acquired by BioMarin early 2015 for up to USD 840 million. Before joining Prosensa, Hans worked at Genzyme for five years in various executive roles, including as Vice President for Global Marketing and Strategic Development of Genzyme´s product portfolio for rare genetic diseases. Prior to Genzyme, he spent 17 years at Organon, both at corporate level and in country operations which included assignments in Asia and Europe.

Currently, Hans is Board Member of the Core team of the Dutch Top Sector Life Sciences & Health, Chaiman of the biopharmaceutical company Complix, Independent Member of the Supervisory Board of Prosensa Holding, Board Member of Hansa Medical AB (publ), Non-executive Director of Sobi (Swedish Orphan Biovitrum, publ) and Board Member of Wilson Therapeutics AB. He is past Chairman of Nefarma, the Dutch Association of Research Based Pharmaceutical Industry and was previously also Member of the Biotechnology Industry Organization’s Emerging Companies Section Governing Board. He has a PharmD from Utrecht University.

Sponsors & Partners
Main partner
Host sponsor
Host sponsor
Platinum sponsor
Platinum sponsor
Platinum sponsor
Platinum sponsor
Gold sponsor
Silver sponsor
Award sponsor
Award sponsor
© 2017 Innovation for Health